Pharmacological lipid-lowering therapies for primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia: a systematic review and network meta-analysis.

Cochrane Database Syst RevSep 16, 2026 (epub)
Clinical ResearchCardiology

Kamyar Shokraee, Brenda Bongaerts, Petek Eylul Taneri et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis aims to evaluate the effects and safety of various lipid-lowering therapies, including statins and non-statin options, for preventing cardiovascular disease in adults with dyslipidaemia. The study seeks to rank these therapies relative to placebo or no treatment.

Key findings

  • The review compares high, moderate, and low-intensity statin regimens against non-statin therapies.
  • It assesses both primary and secondary prevention of cardiovascular disease.
  • The analysis includes a relative ranking of therapies based on their effectiveness.

Why it matters

Understanding the comparative effectiveness and safety of lipid-lowering therapies is crucial for clinicians to make informed treatment decisions for patients with dyslipidaemia, ultimately aiming to reduce cardiovascular disease risk.

Source

PubMed · PMID 42746925

Published in Cochrane Database Syst Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.